AlexanderPhilipovskiyMDMD., PhD(He/Him)

PubMed

• First results of migoprotafib, a potent and highly selective Src homology-2 domain-containing phosphatase 2 (SHP2) inhibitor in patients with advanced solid tumors.
  Melissa L Johnson, Beni B Wolf, Judy S Wang, Alexander Philipovskiy, Geoffrey I Shapiro
  Molecular Cancer Therapeutics. 2024-12-05
• 6 citations
  The impact of minimally invasive surgery and frailty on post-hepatectomy outcomes.
  Felipe B Maegawa, Maria Ahmad, Katherine Aguirre, Sherif Elhanafi, Shintaro Chiba
  HPB. 2022-09-01
• 1 citations
  Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer.
  Sayed Reshad Ghafouri, Suvarna Guvvala, Catherine Jones, Alexander Philipovskiy
  Journal of Investigative Medicine. 2022-08-01

Journal Articles

• Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.  
  Umeanaeto O, Gamboa J, Diaz J, Hakim MN, Corral J, Philipovskiy A, Gaur S, Anticancer Research, 9/1/2019
• Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC).  
  Philipovskiy A, Corral J, Dwivedi KA, Heydarian R, Gaur S., In vivo, 6/1/2019

Abstracts/Posters

• Retrospective Study of Incidence and Survival for Patients with Hematologic Malignancies Residing at the U.S./Mexico Border
  Alexander Philipovskiy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Outcomes of Hispanic/Latino women with triple-negative breast cancer who achieve a complete pathologic response after neoadjuvant chemotherapy. 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019